# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.
10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfo...